Blood Glucose Meters & Associated Consumables

CPV: Blood-testing reagents

Procedure method

Award procedure without prior publication of a call for competition

Legal basis

CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)

Procurement category

Goods

Notice status

Awarded without competition

Procurement threshold

Unspecified in notice

Regulatory regime

Standard

Commercial structure

Stand-alone contract (no framework)

Competition type

Direct award (no call for competition)

GPA / WTO covered

Unspecified in notice

Recurring procurement

Unspecified in notice

First published

21 Oct 2021, 17:04 BST

Last source update

21 Oct 2021, 17:04 BST

FTS notice number

2021/S 000-026448

Classification (CPV)

Blood-testing reagents

Delivery area

Wales (UKL18)

Official registry OCID

ocds-h6vhtk-02eebd Find a Tender

Why no open competition

The procurement falls outside the scope of application of the directive

Published justification

The current contract with Abbott Laboratories Ltd ended on the 30th September 2021. The Health Board's intention was to enter into a 2 year contract with Abbott Laboratories Ltd through a direct award under the terms of a Public Sector Framework. This would enable sufficient time for NWSSP Shared Services Procurement to undertake a formal market-test exercise, to award a new All Wales Framework in Autumn 2023. Currently, the Health Board's POCT Service are not able to contemplate an alternative supplier for the reasons outlined below:

Within SBU there are 3,279 active operators and the SBU POCT Team also support another 937 on the Princess of Wales (PoW) site under the terms of an SLA

The migration of operators to a completely new device would need to be completed on a rolling basis with full training for every member of staff. The POCT Team is not in a position to support this due to the extra training demands in relation to Covid-19 and the clinical areas are still finding it difficult to release staff to attend training, due to staffing pressures.

The current management of testing allows for staff to move flexibly from one area or site to another. During the process of migration this flexibility will be lost to a degree with some areas using the new meter and other areas using the existing meter, this could expose the HB to risk, given current staffing pressures.

Unfortunately, the Health Board cannot find a Public Sector Framework with which to engage with Abbott Laboratories Ltd at this time and therefore, there is no opportunity to make a compliant direct award.

For the reasons outlined above and to ensure continuity of service for patient care, the Health Board has no option but to extend for two years without any formal underpinning Framework arrangement.

In the interim the Health Board is committed to the All Wales market test which will come to fruition in Autumn 2023, for a new formal contract for Point of Care Blood Glucose & Ketone Testing.

Publisher note: NOTE: To register your interest in this notice and obtain any additional information please visit the Sell2Wales Web Site at https://www.sell2wales.gov.wales/Search/Search_Switch.aspx?ID=115068. (WA Ref:115068)

• Abbott Laboratories LtdAwarded supplier Abbott House, Vanwall Business Park, Maidenhead, UK, SL64XEContact phoneShow contact details

No document links were published on the notice.